Program
Rituximab
Also written as “rituximab”, “rituximab [MabThera/Rituxan]” and “Rituximab SC”.
Its studies are mostly in Arthritis, Rheumatoid · Lymphoma, Non-Hodgkin · Lymphoma, Large B-Cell, Diffuse · Lymphoma, Follicular · Leukemia, Lymphocytic, Chronic, B-Cell, led by 20 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 781 open or running | phase 4since Jan 18, 2007 | Apr 1, 2003 | none ahead |
| SymBio Pharmaceuticals | 50 open or running | phase 3since Dec 10, 2017 | Nov 18, 2008 | none ahead |
| AbbVie | 40 open or running | phase 3since Jun 9, 2014 | Apr 20, 2012 | none ahead |
| AstraZeneca | 42 open or running | phase 4since Aug 23, 2023 | Apr 8, 2016 | Oct 31, 2028phase 2 · NCT05951959 |
| Biogen | 40 open or running | phase 4since Aug 23, 2004 | Mar 31, 2003 | none ahead |
| Takeda | 40 open or running | phase 3since Apr 7, 2006 | Jun 11, 2004 | none ahead |
| Biocad | 30 open or running | phase 3since Oct 3, 2012 | Oct 3, 2012 | none ahead |
| Celltrion | 30 open or running | phase 1since Feb 8, 2012 | Feb 8, 2012 | none ahead |
| favrille | 30 open or running | phase 3since Aug 4, 2004 | Aug 4, 2004 | none ahead |
| GlaxoSmithKline | 20 open or running | phase 3since Oct 13, 2017 | Dec 14, 2015 | none ahead |
| ImmunityBio | 22 open or running | phase 1since Oct 19, 2022 | Oct 19, 2022 | Oct 2027phase 1 · NCT06334991 |
| mabion-sa | 20 open or running | phase 3since Jun 9, 2015 | Jun 9, 2015 | none ahead |
| Merck | 20 open or running | phase 1since May 18, 2011 | May 18, 2011 | none ahead |
| Sarah Cannon Research Institute | 20 open or running | phase 2since Nov 7, 2005 | Nov 7, 2005 | none ahead |
| Amgen | 10 open or running | phase 2since Jul 5, 2000 | Jul 5, 2000 | none ahead |
| Bayer | 10 open or running | phase 2since Jul 8, 2004 | Jul 8, 2004 | none ahead |
| mabscale-llc | 11 open or running | phase 1since Dec 7, 2023 | Dec 7, 2023 | none ahead |
| pharmatech | 10 open or running | phase 2since Jan 26, 2009 | Jan 26, 2009 | none ahead |
| probiomed-s-a-de-c-v | 10 open or running | phase 3since Jan 8, 2011 | Jan 8, 2011 | none ahead |
| Sinocelltech Group | 10 open or running | phase 1since Jul 30, 2014 | Jul 30, 2014 | none ahead |
Also a collaborator on its studies: icon-clinical-research, Johnson & Johnson, Bristol-Myers Squibb, Merck KGaA, Darmstadt, Germany, UCB, Eli Lilly, Teva Pharmaceutical Industries, roche-pharma-ag and chiron-corporation.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jan 7, 2011.
- Oct 13, 2017Phase 3 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT03312907 · 292 enrolled · United States, Argentina, Brazil and more
- Dec 10, 2017Phase 3 study in Lymphoma, Large B-Cell, DiffuseSymBio Pharmaceuticals · NCT03372837 · 40 enrolled · Japan
- Mar 6, 2019Phase 2 study in LymphomaSymBio Pharmaceuticals · NCT03900377 · 37 enrolled · Japan
- Jul 22, 2019Phase 1 study in Multiple MyelomaHoffmann-La Roche · NCT04045028 · 41 enrolled · United States, Korea, Republic of
- Nov 25, 2020Phase 2 study in Lymphoma, Large B-Cell, DiffuseHoffmann-La Roche · NCT04660799 · 50 enrolled · China
- Jan 13, 2021Phase 3 study in RecurrenceHoffmann-La Roche · NCT04712097 · 478 enrolled · United States, Australia, Brazil and more
- Mar 8, 2021Phase 1 study in Lymphoma, Large B-Cell, DiffuseHoffmann-La Roche · NCT04790903 · 50 enrolled · United States, France, Italy and more
- May 3, 2022Phase 1 study in Lymphoma, Large B-Cell, DiffuseHoffmann-La Roche · NCT05364424 · 43 enrolled · United States
- Oct 19, 2022ImmunityBio's first study: phase 1 study in RecurrenceNew to ImmunityBioImmunityBio · NCT05618925 · 20 planned · United States
- Jun 5, 2023Phase 2 study in Lymphoma, Mantle-CellAstraZeneca · NCT05951959 · 108 enrolled · United States, Australia, Brazil and more
- Jul 11, 2023Phase 2 study in Lymphoma, Large B-Cell, DiffuseAstraZeneca · NCT05952024 · 80 planned · United States, Brazil, Puerto Rico and more
- Aug 23, 2023Phase 4 study in HypophosphatasiaAstraZeneca · NCT06015750
- Dec 7, 2023mabscale-llc's first study: phase 1 study in Arthritis, RheumatoidNew to mabscale-llcmabscale-llc · NCT06175338 · 208 enrolled · Russian Federation
- Mar 5, 2024Phase 1 study in Non-Hodgkin Lymphoma Refractory/ RelapsedImmunityBio · NCT06334991 · 20 enrolled · South Africa
Ahead
- Oct 2027Primary completion: phase 1 study in Non-Hodgkin Lymphoma Refractory/ RelapsedImmunityBio · NCT06334991
- Oct 31, 2028Primary completion: phase 2 study in Lymphoma, Mantle-CellAstraZeneca · NCT05951959
- Apr 22, 2029Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseAstraZeneca · NCT05952024
TargetBeta
“A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule
Other programs on MS4A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ocrelizumabrule | Hoffmann-La Roche | phase 4 | 42 |
| obinutuzumabrule | Hoffmann-La Roche | phase 4 | 42 |
| ublituximabrule | TG Therapeutics | phase 3 | 23 |
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| Anti-CD20 Monoclonal Antibody MIL62rule | beijing-mabworks-biotech-co-ltd | phase 3 | 10 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| zuberitamabrule | bioray-pharmaceutical-co-ltd | phase 3 | 3 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
Studies
The newest 60 of 124 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06334991Non-Hodgkin Lymphoma Refractory/ Relapsed · South Africa | 1 | Active, not recruiting | ImmunityBio | Oct 2027 | 20 |
| NCT06175338Arthritis, Rheumatoid · Russian Federation | 1 | Active, not recruiting | mabscale-llc | Nov 2024 | 208 |
| NCT06015750Hypophosphatasia | 4 | Withdrawn | AstraZeneca | Mar 13, 2030 | 0 |
| NCT05952024Lymphoma, Large B-Cell, Diffuse · United States, Brazil, Puerto Rico and more | 2 | Recruiting | AstraZeneca | Apr 22, 2029 | 80 |
| NCT05951959Lymphoma, Mantle-Cell · United States, Australia, Brazil and more | 2 | Active, not recruiting | AstraZeneca | Oct 31, 2028 | 108 |
| NCT05618925Recurrence · United States | 1 | Recruiting | ImmunityBio | May 15, 2026 | 20 |
| NCT05364424Lymphoma, Large B-Cell, Diffuse · United States | 1 | Completed | Hoffmann-La Roche | Oct 15, 2025 | 43 |
| NCT04790903Lymphoma, Large B-Cell, Diffuse · United States, France, Italy and more | 1 | Terminated | Hoffmann-La Roche | May 21, 2024 | 50 |
| NCT04712097Recurrence · United States, Australia, Brazil and more | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 3, 2026 | 478 |
| NCT04660799Lymphoma, Large B-Cell, Diffuse · China | 2 | Completed | Hoffmann-La Roche | May 23, 2022 | 50 |
| NCT04045028Multiple Myeloma · United States, Korea, Republic of | 1 | Terminated | Hoffmann-La Roche | Mar 28, 2023 | 41 |
| NCT03900377Lymphoma · Japan | 2 | Completed | SymBio Pharmaceuticals | Sep 9, 2020 | 37 |
| NCT03372837Lymphoma, Large B-Cell, Diffuse · Japan | 3 | Completed | SymBio Pharmaceuticals | Dec 31, 2019 | 40 |
| NCT03312907Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 3 | Completed | GlaxoSmithKline | May 29, 2020 | 292 |
| NCT02735876Lymphoma, Mantle-Cell | 3 | Withdrawn | AstraZeneca | Jun 2020 | 0 |
| NCT02744196Arthritis, Rheumatoid | 3 | Completed | Biocad | Feb 2017 | 159 |
| NCT02693210Arthritis, Rheumatoid · Australia, Belgium, Canada and more | 2 | Completed | Hoffmann-La Roche | Aug 2002 | 161 |
| NCT02631538Sjogren's Syndrome · Argentina, Canada, France and more | 2 | Completed | GlaxoSmithKline | Jun 23, 2020 | 86 |
| NCT02617485Lymphoma, Large B-Cell, Diffuse · Bosnia and Herzegovina, Croatia, Georgia and more | 3 | Completed | mabion-sa | Aug 2017 | 143 |
| NCT02600897Recurrence · United States, Spain, United Kingdom | 2 | Completed | Hoffmann-La Roche | Dec 15, 2021 | 114 |
| NCT02569996Lymphoma, Follicular · Hungary | 3 | Completed | Hoffmann-La Roche | Aug 2013 | 124 |
| NCT02533401Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Venezuela | 2 | Completed | Hoffmann-La Roche | Dec 2014 | 34 |
| NCT02468791Arthritis, Rheumatoid · Bosnia and Herzegovina, Georgia, Poland and more | 3 | Completed | mabion-sa | May 2017 | 709 |
| NCT02406092Lymphoma, Non-Hodgkin · Algeria, Morocco, Tunisia | 3 | Completed | Hoffmann-La Roche | Jun 30, 2021 | 139 |
| NCT02383589Pemphigus · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Nov 28, 2018 | 135 |
| NCT02257567Lymphoma · United States, Australia, Canada and more | 2 | Completed | Hoffmann-La Roche | Oct 21, 2021 | 331 |
| NCT02206308Lymphoma, B-Cell | 1 | Completed | Sinocelltech Group | Jul 2013 | 15 |
| NCT02165397Waldenstrom Macroglobulinemia · United States, Australia, Canada and more | 3 | Completed | AbbVie | Nov 7, 2019 | 181 |
| NCT02115997Granulomatosis with Polyangiitis · India | 4 | Completed | Hoffmann-La Roche | Jun 7, 2022 | 30 |
| NCT02097745Arthritis, Rheumatoid · United States, Belgium, Canada and more | 3 | Completed | Hoffmann-La Roche | Jun 2013 | 341 |
| NCT02093026Arthritis, Rheumatoid · United States, Australia, Belgium and more | 2 | Completed | Hoffmann-La Roche | Dec 2012 | 465 |
| NCT02079532Arthritis, Rheumatoid · Germany | 3 | Completed | Hoffmann-La Roche | Nov 2010 | 302 |
| NCT02077166Lymphoma, Large B-Cell, Diffuse · United States, Belgium, Germany and more | 2 | Completed | AbbVie | Dec 17, 2020 | 138 |
| NCT02055820Lymphoma, Non-Hodgkin · United States, Australia, Austria and more | 2 | Completed | Hoffmann-La Roche | Jun 28, 2017 | 267 |
| NCT02006706Arthritis, Rheumatoid · Serbia | 3 | Completed | Hoffmann-La Roche | Nov 23, 2007 | 15 |
| NCT02013817Leukemia, Lymphocytic, Chronic, B-Cell · Austria | 2 | Completed | Hoffmann-La Roche | Sep 24, 2012 | 43 |
| NCT01998893Lymphoma, Non-Hodgkin · Germany | 2 | Completed | Hoffmann-La Roche | Feb 2008 | 38 |
| NCT01987505Lymphoma, Non-Hodgkin · Spain | 3 | Completed | Hoffmann-La Roche | Apr 11, 2017 | 140 |
| NCT01980654Lymphoma, Follicular · United States | 2 | Completed | AbbVie | Nov 2017 | 80 |
| NCT01889069Lymphoma · Italy | 3 | Completed | Hoffmann-La Roche | May 28, 2019 | 159 |
| NCT01873443Arthritis, Rheumatoid · Korea, Republic of | 1 | Completed | Celltrion | Oct 2014 | 87 |
| NCT01759030Arthritis, Rheumatoid · Belarus, India, Russian Federation and more | 3 | Completed | Biocad | Jul 2015 | 181 |
| NCT01750697Granulomatosis with Polyangiitis · United States, Canada, France and more | 2 | Completed | Hoffmann-La Roche | May 10, 2018 | 25 |
| NCT01724021Lymphoma, Large B-Cell, Diffuse · Argentina, Australia, Austria and more | 3 | Completed | Hoffmann-La Roche | Jan 2015 | 743 |
| NCT01718691Low-grade B Cell Non-Hodgkin's Lymphoma · Japan | 2 | Completed | SymBio Pharmaceuticals | Nov 2013 | 70 |
| NCT01701232Lymphoma, Follicular · Colombia, India, Russian Federation and more | 3 | Completed | Biocad | Jan 2017 | 174 |
| NCT01671904Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Germany | 1 | Completed | Hoffmann-La Roche | Aug 17, 2018 | 84 |
| NCT01649856Lymphoma, Large B-Cell, Diffuse · Algeria, Argentina, Belgium and more | 3 | Completed | Hoffmann-La Roche | Oct 21, 2014 | 572 |
| NCT01594229Lymphoma, Non-Hodgkin · United States | 1 | Completed | AbbVie | Jul 14, 2020 | 60 |
| NCT01534949Lymphoma, Large B-Cell, Diffuse · Korea, Republic of | 1 | Terminated | Celltrion | Feb 2013 | 1 |
| NCT01534884Arthritis, Rheumatoid · Korea, Republic of | 1 | Completed | Celltrion | Aug 2013 | 154 |
| NCT01461928Lymphoma, Non-Hodgkin · Albania, Argentina, Austria and more | 3 | Completed | Hoffmann-La Roche | Jun 2, 2018 | 692 |
| NCT01397825Lymphoma, Large B-Cell, Diffuse · United States, Italy, Spain and more | 2 | Completed | Takeda | Feb 5, 2015 | 45 |
| NCT01390441Arthritis, Rheumatoid | 1 | Terminated | Merck | Apr 2014 | 100 |
| NCT01392716Lymphoma, Non-Hodgkin · France | 2 | Completed | Hoffmann-La Roche | Feb 2006 | 48 |
| NCT01388959Lymphoma, Non-Hodgkin · France | 2 | Completed | Hoffmann-La Roche | Apr 2004 | 40 |
| NCT01382940Arthritis, Rheumatoid · United States | 4 | Completed | Hoffmann-La Roche | Jan 6, 2013 | 351 |
| NCT01370694Lymphoma, Follicular | 1 | Terminated | Merck | Dec 1, 2014 | 7 |
| NCT01277172Lymphoma, Large B-Cell, Diffuse · Mexico | 3 | UNKNOWN | probiomed-s-a-de-c-v | Sep 2011 | 54 |
| NCT01272908Arthritis, Rheumatoid · Canada, Sweden | 3 | Completed | Hoffmann-La Roche | Mar 12, 2009 | 120 |
How it is read
Names in the registry
- “Rituximab”, 104 entries
- “rituximab”, 34 entries
- “rituximab [MabThera/Rituxan]”, 23 entries
- “Rituximab SC”, 2 entries
- “MK-8808”, 2 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 34 studies
- Lymphoma, Non-Hodgkin, 33 studies
- Lymphoma, Large B-Cell, Diffuse, 23 studies
- Lymphoma, Follicular, 21 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 18 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.